Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Its commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration and retinal vein occlusion.

Type
Public
HQ
Alpharetta, US
Founded
2003
Size (employees)
125 (est)
Alimera Sciences was founded in 2003 and is headquartered in Alpharetta, US
Report incorrect company information

Key People/Management at Alimera Sciences

Ken Greene

Ken Greene

CSO
Susan Caballa

Susan Caballa

Sr. Vice President, Regulatory & Medical Affairs
Philip Ashman

Philip Ashman

SVP & European Managing Director
Rick Eiswirth

Rick Eiswirth

President & CFO
Dave Holland

Dave Holland

SVP of Sales & Marketing
Show more

Alimera Sciences Office Locations

Alimera Sciences has offices in Hampshire, Alpharetta, Berlin and Lisbon
Alpharetta, US (HQ)
6120 Windward Pkwy
Berlin, DE
21 Cicerostraße
Hampshire, GB
Wellesley Rd
Show all (4)
Report incorrect company information

Alimera Sciences Financials and Metrics

Alimera Sciences Revenue

Alimera Sciences's revenue was reported to be $34.33 m in FY, 2016 which is a 53% increase from the previous period.
USD

Revenue (Q1, 2018)

9.8 m

Net income (Q1, 2018)

(7.7 m)

Market capitalization (11-Jul-2018)

69.4 m

Closing share price (11-Jul-2018)

1

Cash (30-Jun-2017)

26.9 m
Alimera Sciences's current market capitalization is $69.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.9 m8.4 m22.4 m34.3 m

Revenue growth, %

350%166%53%

Cost of goods sold

1.9 m

Gross profit

9 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

758 k2.1 m2.2 m2.4 m3.9 m5.8 m6.9 m5.8 m9.6 m8.3 m6.6 m10.4 m9.8 m

Cost of goods sold

57 k564 k376 k

Gross profit

701 k1.5 m1.8 m

Gross profit Margin, %

92%73%83%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

12.6 m76.7 m31.1 m31 m

Accounts Receivable

500 k850 k9.8 m13.8 m

Inventories

3.5 m3.2 m2.7 m446 k

Current Assets

18.6 m83.3 m45.2 m47.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

23.1 m41.3 m42 m61.4 m61.3 m48.1 m39.3 m23.9 m16.6 m33.9 m26.7 m26.9 m

Accounts Receivable

464 k1.3 m1 m1.1 m3.4 m7.7 m9.4 m9.1 m13.3 m13.4 m10.8 m13.6 m

Inventories

3 m1.2 m1.4 m1.7 m2.1 m1.6 m1.7 m1.4 m1.2 m913 k802 k1.1 m

Current Assets

30.1 m46.5 m47.5 m67.3 m70.3 m61.1 m53.4 m37.2 m34.7 m51.6 m40.5 m44.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(46.2 m)(35.9 m)(30.6 m)(33.2 m)

Depreciation and Amortization

138 k659 k2.6 m2.8 m

Inventories

(1.4 m)206 k405 k1 m

Accounts Payable

(259 k)3 m(487 k)1.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(31.5 m)(20.8 m)(19.6 m)(26.7 m)(9.8 m)(18.4 m)(19.9 m)(11.1 m)(18 m)(27.2 m)(6.7 m)(9.5 m)(7.7 m)

Depreciation and Amortization

101 k36 k69 k151 k558 k1.2 m1.9 m689 k1.4 m2.1 m666 k1.3 m649 k

Inventories

(2.2 m)548 k400 k(9 k)(455 k)(16 k)(88 k)164 k301 k612 k(361 k)(719 k)299 k

Accounts Payable

717 k111 k122 k1.3 m272 k(1.2 m)(1.4 m)(1.5 m)264 k(2.1 m)(1.1 m)572 k(992 k)
Show all financial metrics
Report incorrect company information

Alimera Sciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Alimera Sciences News and Updates

Alimera Sciences Appoints Mary T. Szela to its Board of Directors

ATLANTA, June 21, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced Mary T. Szela has joined its Board of Directors. Ms. Szela is currently the Chief...

Alimera Sciences Appoints Mary T. Szela to its Board of Directors

ATLANTA, June 21, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced Mary T. Szela has joined its Board of Directors. Ms. Szela is currently the Chief...
Report incorrect company information

Alimera Sciences Company Life and Culture

Report incorrect company information